GE HealthCare doubles down on nuclear medicine: How AI, radiopharmaceuticals, and imaging platforms are reshaping precision medicine infrastructure

Title

GE HealthCare Steps Up Its Nuclear Medicine Push: How AI, Radiopharmaceuticals, and Imaging Platforms Are Reshaping the Infrastructure of Precision Medicine

Introduction

Nuclear medicine is moving from a relatively niche specialty capability to broader clinical infrastructure. What GE HealthCare showcased at the 2026 SNMMI annual meeting was not a single device, but an integrated portfolio built around PET, SPECT, radiopharmaceuticals, AI-based quantitative analysis, and workflow integration. This move sends a clear signal to the industry: the logic of competition in nuclear medicine is shifting from “selling equipment” to “building an ecosystem.”

For global Digital Health, AI Healthcare, and Medical Devices markets, the significance of nuclear medicine’s expansion lies not only in imaging technology itself, but in how it redefines precision care pathways, hospital operating efficiency, and the organization of the radiopharmaceutical supply chain.

Industry Context

The growth of nuclear medicine first stems from changes on the clinical demand side. GE HealthCare noted in its materials that the adoption of theranostics is accelerating, and demand for radiopharmaceuticals is also rising. At the same time, the global nuclear medicine market is expected to grow from about $7.8 billion in 2024 to more than $30.7 billion by 2034. While such forecasts should still be treated cautiously, they at least point to one fact: nuclear medicine has entered a window of attention for capital, industry, and clinical practice alike.

The core of this wave of change is not a single technological breakthrough, but the simultaneous maturation of multiple variables:

• Ongoing progress in molecular imaging and radiopharmaceutical R&D
• AI-assisted quantitative analysis beginning to enter clinical workflows
• PET and SPECT platforms placing greater emphasis on speed, quantifiability, and standardization
• Healthcare systems starting to focus on outpatient, community-based, and mobile imaging models

From the perspective of the Healthcare Industry, nuclear medicine’s past high barriers mainly came from three constraints: expensive equipment, complex workflows, and limited tracer availability. Now, the industry is trying to use AI, modular equipment, and localized production capabilities to break down these bottlenecks.

Key Developments

1. AI is shifting from a “post-processing tool” to part of the nuclear medicine workflow

GE HealthCare highlighted several AI-related software capabilities in this release. Among them, MIM LesionID Pro has received U.S. FDA 510(k) clearance and can be used for whole-body tumor burden analysis; MIM KineticID is currently in the 510(k) submission stage and is aimed at dynamic PET imaging and kinetic modeling.The industry significance of these tools lies in the fact that they are not only improving efficiency, but also driving nuclear medicine from “experience-based judgment” toward “reproducible quantification.” In clinical multicenter settings, standardized analysis has always been a pain point, and AI quantification software has precisely entered this part of the workflow.

For hospitals, this means that steps such as image reading, segmentation, and cross-modality registration may become further automated. For companies, it means imaging software is shifting from an accessory module to a core layer of value creation. For investors, it also means that Medical AI is no longer limited to general-purpose image recognition, but is moving into the more specialized molecular imaging field.

2. Competition in PET/CT and SPECT/CT platforms is now centered on “high throughput + high sensitivity + quantifiability”

On the hardware side, GE HealthCare showcased multiple platforms, including Omni Legend PET/CT, StarGuide SPECT/CT, and digital imaging systems for specific applications. The company emphasized that these platforms support faster scanning, higher sensitivity, and better quantitative capabilities.

This shows that the competitive logic of nuclear medicine equipment is changing. In the past, hospitals mainly focused on resolution and acquisition cost when purchasing imaging equipment; now, as theranostics and longitudinal follow-up needs increase, hospitals care more about:

• Whether scanning speed is sufficient to support higher patient throughput
• Whether quantification results are stable enough
• Whether the equipment can form a closed loop with treatment decisions and therapy monitoring

Such capabilities are especially important for large medical centers, oncology hospitals, and neurological specialty institutions. That is also why nuclear medicine equipment manufacturers are increasingly looking like platform-based healthcare technology companies rather than traditional hardware suppliers.

3. Radiopharmaceuticals and localized production capabilities are becoming key to market expansion

GE HealthCare also showcased compact cyclotron solutions such as MINItrace Magni, used to support in-hospital production of PET tracers and radiometals, including key materials such as Gallium-68.

This direction is very important because the real bottleneck in nuclear medicine expansion is often not “whether there is equipment,” but “whether there are stable and accessible tracers.” Once local production capacity improves, hospitals are more likely to turn nuclear medicine from a scarce service available only at a few major centers into a more routine clinical capability.

This is also why the radiopharmaceutical supply chain, cyclotrons, logistics cold chains, and regulatory approvals are all becoming important investment themes in the Healthcare Innovation industry chain.

4. Clinical applications are expanding along three main tracks: cardiology, neurology, and oncology

GE HealthCare’s showcase covered several typical scenarios:

• Cardiology: Flyrcado is used for PET myocardial perfusion imaging, aiming to expand accessibility in community healthcare settings
• Neurology: Vizamyl combined with MIMneuro supports more consistent interpretation of amyloid PET
• Oncology: The combination of StarGuide, iRT, and MIM is aimed at tumor burden assessment, treatment planning, and response monitoring

• This reflects that nuclear medicine is evolving from a “diagnostic tool” toward an “integrated diagnosis-and-treatment platform.”- Cardiac: Flyrcado is used for PET myocardial perfusion imaging, with the goal of expanding access in community healthcare settings
• Neurology: Vizamyl combined with MIMneuro supports more consistent interpretation of amyloid PET
• Oncology: The StarGuide, iRT, and MIM combination is geared toward tumor burden assessment, treatment planning, and response monitoring

This reflects how nuclear medicine is evolving from a “diagnostic tool” into an integrated diagnosis-and-treatment platform. Especially in neurodegenerative diseases and precision oncology, the links between imaging, quantification, and treatment selection are becoming increasingly close.

Market Implications

Which companies may benefit?

This trend will benefit several types of companies:

1. Imaging equipment manufacturers: Companies with PET/CT, SPECT/CT, quantitative software, and deep learning capabilities will have an advantage in procurement by top-tier hospitals. 2. Radiopharmaceutical and tracer suppliers: As demand for PET and theranostics expands, the importance of a stable supply chain increases. 3. AI imaging software companies: Vendors focused on automated segmentation, quantitative analysis, longitudinal tracking, and multimodal workflow integration may gain stronger pricing power. 4. In-house nuclear medicine infrastructure providers: Including cyclotrons, radiation protection, workflow software, and operations and maintenance service companies.

From a capital perspective, the market will not only reward companies that “have AI,” but will more strongly favor those that can integrate AI, equipment, reagents, and clinical workflows. That is exactly the end-to-end strategy GE HealthCare showcased this time.

Which hospitals or institutions are adopting it?

According to public materials, GE HealthCare said its technologies are being oriented toward broader healthcare systems, community settings, and mobile imaging models. The materials also quoted the head of nuclear medicine at Mount Sinai Health System, emphasizing that advanced imaging, quantitative analysis, and innovative radiopharmaceuticals are helping clinicians make earlier, more informed decisions.

This indicates that adopters of nuclear medicine are gradually expanding from traditional large academic medical centers to broader hospital networks and regional healthcare systems. The real change is not whether a particular hospital installs a piece of equipment, but whether the healthcare system begins to incorporate nuclear medicine into standard pathways.

Challenges And Risks

Although the outlook is clear, scaling nuclear medicine still faces multiple risks.

First, regulatory barriers are high. Radiopharmaceuticals, imaging equipment, and AI software each involve different approval pathways, and delays at any stage will affect the pace of commercialization.Second, infrastructure requirements are complex. Nuclear medicine requires not only equipment, but also radiation management, tracer supply, professional staff training, and workflow integration. For small and medium-sized hospitals, these are all real barriers.

Third, standardization has still not been fully resolved. Although AI quantification tools can improve consistency, cross-center data, differences in indications, and clinical threshold standards still need to be further established.

Fourth, cost and reimbursement remain key variables. If insurance reimbursement and hospital budgets cannot match the value of the technology, the pace of nuclear medicine expansion may be lower than market expectations.

Therefore, although nuclear medicine is seen as a high-growth sector, it is not a market that can rapidly penetrate with technology alone; rather, it is an industry highly dependent on the coordination of policy, infrastructure, and reimbursement systems.

Future Outlook

Over the next 3 to 5 years, nuclear medicine will most likely continue evolving along three directions.

First, AI quantitative analysis will become further embedded in clinical workflows. From reading assistance to tumor burden assessment, dynamic PET quantification, and efficacy monitoring, software will increasingly resemble part of a “clinical operating system.”

Second, the radioactive drug supply chain will accelerate localization. In-hospital production, regional center supply, and business models for materials with shorter half-lives may become key to market competition.

Third, nuclear medicine will spread from top-tier tertiary centers to a broader medical network. Especially in cardiovascular, neurological, and oncology fields, more hospitals will seek to incorporate nuclear medicine into standard diagnosis and treatment pathways, rather than using it only as a research or high-end supplementary service.

This also means that future competition will no longer be just a contest of individual product performance, but a competition in system capabilities centered on data, workflows, regulation, and the supply chain.

Conclusion

GE HealthCare’s presentation at SNMMI 2026 was, in essence, answering an industry question: the next stage of growth in nuclear medicine will not rely solely on better equipment, but on a more complete technology stack, a more stable supply system, and more reproducible clinical pathways. For the global Healthcare Technology and AI Healthcare industries, the real focus of this sector has already shifted from “whether the technology is advanced” to “who can turn the technology into scalable medical infrastructure.”